COMMUNIQUÉS West-GlobeNewswire

TRACON Pharmaceuticals Announces $38.7 Million Private Placement
23/03/2018
SAN DIEGO, March 23, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON ), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer [...]
Vericel Reports Publication of Results from the Phase 3 SUMMIT Extension Study Demonstrating Sustained Clinical Benefit of MACI Out to Five Years
23/03/2018
CAMBRIDGE, Mass., March 23, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL ), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the publication of [...]
MPI publishes Annual report for 2017
23/03/2018
Hoersholm, Denmark, March 23, 2018 - Medical Prognosis Institute A/S ("MPI") publishes the Annual Report for 2017. The complete report is available in the attached document. A summary of the Annual Report is presented [...]
Nuvus Corp Signs Letter of Intent With Kunjani Group - Nuvus Brings Its Bio-Agriculture & Blockchain Technology Solutions to Africa
23/03/2018
Johannesburg, South Africa, March 23, 2018 (GLOBE NEWSWIRE) -- JOHANNESBURG, South Africa — NUVUS Corp., a pioneer in bio-agricultural technology, announced today that it has entered into a Letter of Intent with Kunjani [...]
Calithera to Present at Needham & Company 17th Annual Healthcare Conference
23/03/2018
SOUTH SAN FRANCISCO, Calif., March 23, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA ), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today [...]
OPKO Health Enrolls First Patient in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes
23/03/2018
MIAMI, March 23, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK ) has enrolled the first patient in a Phase 2b dose escalation trial of OPK88003, a once-weekly oxyntomodulin therapy containing dual agonist [...]
Cellular Biomedicine Group (CBMG) Announces Annual Meeting of Stockholders
23/03/2018
SHANGHAI, China and CUPERTINO, Calif., March 23, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc . (NASDAQ: CBMG ) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of [...]
Intercept Announces Multiple New Ocaliva® (obeticholic acid) Data Presentations at the International Liver Congress™ 2018
23/03/2018
NEW YORK, March 23, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat [...]
PLx Pharma Inc. Reports Fourth Quarter and Full Year 2017 Results
23/03/2018
HOUSTON, March 23, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP ) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 [...]
Shire plc : District Court Issues Ruling Finding Adderall XR® Patents Infringed
23/03/2018
District Court Issues Ruling Finding Adderall XR® Patents Infringed Cambridge, Mass., USA - March 23, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces that its subsidiary, Shire Development LLC, welcomes yesterday's [...]
Accelerate Diagnostics, Inc. Announces Pricing of $150 Million Convertible Notes Offering
23/03/2018
TUCSON, Ariz., March 23, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (“Accelerate Diagnostics”) (NASDAQ: AXDX ) today announced the pricing of $150.0 million aggregate principal amount of 2.50% convertible [...]
Ozempic® approved in Japan for the treatment of type 2 diabetes
23/03/2018
Bagsværd, Denmark, 23 March 2018 - Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Ozempic ® (semaglutide), a new once-weekly analogue of human glucagon-like peptide-1 [...]
UCB: CONVENING NOTICE TO ATTEND THE GENERAL MEETING OF SHAREHOLDERS TO BE HELD AT BLUEPOINT BRUSSELS
23/03/2018
*** Unofficial English translation - For convenience purposes only *** UCB SA/NV - Public Limited Liability Company Allée de la Recherche 60, 1070 Brussels Enterprise nr. 0403.053.608 (RLE Brussels) (" UCB SA/NV " or [...]
UCB: CONVOCATION À L'ASSEMBLÉE GÉNÉRALE DES ACTIONNAIRES QUI SE TIENDRA À BLUEPOINT BRUSSELS
23/03/2018
UCB - société anonyme Allée de la Recherche 60, 1070 Bruxelles n° d'entreprise 0403.053.608 (RPM Bruxelles) (« UCB SA » ou la « Société ») Convocation à l'Assemblée Générale des actionnaires qui se tiendra à BLUEPOINT [...]
INNATE PHARMA : Expansion of mCRC cohort in Phase I trial evaluating monalizumab with Imfinzi
23/03/2018
Partner MedImmune expands colorectal cancer patient cohort in ongoing PHASE I TRIAL EVALUATING MONALIZUMAB IN COMBINATION WITH IMFINZI ® (DURVALUMAB) Additional expansion cohorts to explore the safety and efficacy of [...]
INNATE PHARMA : Extension de cohorte dans la Phase I évaluant monalizumab et Imfinzi dans le cancer colorectal
23/03/2018
MedImmune Étend l'essai de phase I en cours Évaluant MONALIZUMAB en combinaison avec Imfinzi ® (DURVALUMAB) et inclut de nouvelles cohortes de patients atteints d'un cancer colorectal Les cohortes additionnelles [...]
Amicus Therapeutics Announces Approval of Galafold® (Migalastat) for Fabry Disease in Japan
23/03/2018
CRANBURY, N.J., March 22, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD ) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the oral small molecule pharmacological [...]
Updated TACTI-mel Data Presented at the Cambridge Healthtech Institute’s Immuno-Oncology Summit
23/03/2018
SYDNEY, Australia, March 22, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ: IMMP ) (“Immutep” or the “Company”) is pleased to announce the presentation of updated data from its TACTI-mel Phase I clinical [...]
Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
23/03/2018
EXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical secondary progressive MS (SPMS) patients Results demonstrate siponimod also had beneficial [...]

Pages